Canada markets close in 2 hours 39 minutes

Isracann Biosciences Inc. (IPOT.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.0450+0.0050 (+12.50%)
As of 12:46PM EDT. Market open.
Full screen
Previous Close0.0400
Open0.0450
Bid0.0450 x N/A
Ask0.0500 x N/A
Day's Range0.0400 - 0.0450
52 Week Range0.0350 - 0.1700
Volume9,400
Avg. Volume63,423
Market Cap7.123M
Beta (5Y Monthly)-0.22
PE Ratio (TTM)N/A
EPS (TTM)-0.1630
Earnings DateApr 27, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Isracann Biosciences Announces Closing of First Tranche of $0.05 Unit Private Placement

    VANCOUVER, British Columbia, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement. The Company issued 4,679,600 units (the “Units”) at a price of $0.05 per Unit for aggregate gross proceeds of $233,980 (the “Offering”). Each Unit consists of one common share of the Company (a “Share”) and one common share purchase wa

  • GlobeNewswire

    Isracann Biosciences Subsidiary Praesidio Health Submits NPNs to Health Canada

    VANCOUVER, British Columbia, May 19, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted organization with a natural health medicine division in Canada and holdings in Israel, is pleased to announce that its wholly owned subsidiary Praesidio Health has completed the natural product number (NPN) submissions to Health Canada for its first formulations. Praesidio Health (https://www.praesidiohealth.com/) is a Canadian medical re

  • GlobeNewswire

    Isracann Biosciences Renews Leadership to Meet Changing Demands

    VANCOUVER, British Columbia, April 15, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that further to its acquisition of Praesidio Health Inc. as a natural health medicine division, the Company has elected to expand its leadership team effective immediately. As Isracann moves from development to operations, and to better accommodate the integration of natural health medicine (“NHM”) research and development to mee